Acute and Chronic Leukemias

Expert faculty review and share their insights and perspectives on key findings in acute and chronic leukemias presented at the 2021 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2021 Leukemias
    Key Studies in Leukemias: Independent Conference Coverage of ASH 2021
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 06, 2022

    Expires: April 05, 2023

Activities

Venetoclax/Decitabine in Adverse-Risk AML
Venetoclax/Decitabine for Young Adults With Newly Diagnosed ELN Adverse-Risk AML: Phase II Trial Interim Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

ASCEMBL 48-week update
ASCEMBL: 48-Wk Update of Results From the Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

CPX-351 or HMA + Ven in AML
CPX-351 and HMA + Venetoclax as Frontline Therapy in AML: A Retrospective Comparative Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

QUIZ/VEN/DAC in <i>FLT3</i>-Mutated AML
Evaluation of Quizartinib With Venetoclax and Decitabine Therapy in Patients With Newly Diagnosed or R/R FLT3-Mutated AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

Gilteritinib + Venetoclax in R/R AML
Phase Ib Study of Gilteritinib Combined With Venetoclax for R/R Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Ven + Aza in Poor-Risk AML
Pooled Analysis of Impact of TP53 Mutations on Efficacy of Venetoclax + Azacitidine in Patients With AML and Poor-Risk Cytogenetics
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

GMALL 08/2013
GMALL 08/2013: First Results From the Risk-Adapted, MRD-Stratified Trial in Adults With Newly Diagnosed ALL/LBL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

AGILE: Ivosidenib/AZA in AML
AGILE: Phase III Trial of Ivosidenib + Azacitidine vs Placebo + Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

LACEWING
LACEWING: Phase III Study of Gilteritinib + Azacitidine vs Azacitidine for Patients With Newly Diagnosed FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

Aza/Ven/Magrolimab in AML
Combination Therapy With Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

Low-Dose Dasatinib in CP-CML
Low-Dose Dasatinib vs Standard-Dose Dasatinib in Newly Diagnosed CP-CML: A Propensity Score Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

Faculty

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation